Navigation Links
Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
Date:1/25/2013

CHAPEL HILL, N.C., Jan. 25, 2013 /PRNewswire/ -- In order for a new product to gain market foothold in today's competitive pharmaceutical industry, executives must understand where and when to invest in key launch activities. At the same time, product launch leadership has to balance the goals of containing expenditures and generating a successful launch.

To help launch leaders understand effective spend levels for pre-launch and launch activities, research and benchmark consulting firm Best Practices, LLC has published a new study that sheds light on investment levels and frequency across 12 key marketing, education, and payer activities. The study includes overall investment benchmarks by different product types for launch year and each of the three years prior to launch.

The report, "New Product Launch Spend: What it Takes to Win in the U.S. Market" will help leaders in the pharmaceutical sector develop effective launch and pre-launch activity budgets to support successful U.S market entry for new products. The study provides benchmarks that can serve as a reference for brand and launch leaders as they develop budget strategies and allocate funds for new brands.

Key topics covered in the study include:

  • Average Cost: Industry average cost for new pharmaceutical product launch
  • Primary/Specialty Comparison: Cost comparison for specialty versus primary products
  • Budget Allocation: Percentage of budget allocated to 12 key marketing, education and
    market access activities during and prior to launch
  • Activities Timing: Timing for conducting promotional and educational launch activities
  • Future Allocation Trends: Launch activities expected to gain a greater share of the budget in the coming 24-36 months, and activities expected to receive reduced share

The 67-page report is based on a benchmarking study that included 27 brand and marketing executives at 23 leading biopharmaceutical companies. Vice Presidents and Directors make up more than three-quarters of the study's participants and more than half work within marketing functions or departments.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1198.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations. Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
2. New Study Introduces Valuable Tool to Aid Doctors and Patients in Choosing Successful Outcomes for Cheek Rejuvenation
3. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
4. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
5. BioDelivery Sciences Announces Completion of BNX Safety Study
6. Harris Poll Study Links Emotional Connection to Physicians Trust in Pharmaceutical Products
7. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
8. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
9. New Study Shows Promise For Women Needing Mesh-Augmented Pelvic Organ Prolapse (POP) Repair
10. BodyMedia Collaborates on Federal Health Research Study
11. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
(Date:4/24/2017)... Salt Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... in their efforts to encourage sustainability, innovate new strategies to reduce waste, and support ... all-natural herbal remedy provider. They look to nature to find solutions for health issues, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, ... the rarified air of pop and film stardom.(1) Not to be left out is ... smile. Grins now run the gamut from being encrusted with jewels and precious metals ...
Breaking Medicine News(10 mins):